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Abstract
To ascertain the existence of the kallikrein-kinin system in the heart, we have studied in vivo and in vitro whether rat
cardiac tissue expresses kininogen, kallikrein and kinin receptor mRNAs. The reverse transcription-polymerase chain
reaction demonstrated that the ventricular myocardium of adult male rats expressed mRNAs for T- and low-molecular-
weight (L-) kininogens, tissue kallikreins such as true kallikrein and T-kininogenase, and bradykinin B2 receptor, but not
those for high-molecular-weight kininogen and B1 receptor. Lipopolysaccharide (LPS; 0.5 mg/kg, i.v.) increased the levels of
mRNA for T-kininogen at 12 h and the bradykinin B1 receptor at 24 h without affecting that for other components. All of
these mRNAs for the kallikrein-kinin system were also detected in cultured cardiomyocytes derived from neonatal rat
ventricles; dibutyryl cyclic AMP, LPS or inflammatory cytokines such as interleukin-1 and tumor necrosis factor, up-
regulated mRNA expression of T-kininogen, T-kininogenase, or B1 receptor in these cells in vitro. These results suggest that
there are two kinin-generating systems in rat myocardium comprising T-kininogen/T-kininogenase and L-kininogen/true
kallikrein respectively, and that the former may be relatively important in inflammatory diseases or conditions in which
cAMP levels increase in cardiomyocytes. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Numerous studies have demonstrated that angio-
tensin-converting enzyme (ACE) inhibitors can im-
prove survival in patients or animals with severe
heart failure, delay the development of heart failure
in patients or animals with a symptomatic left ven-
tricular dysfunction, and reduce short- and long-term
mortality in patients or animals surviving myocardial
infarction [1^3]. These bene¢cial e¡ects of ACE in-
hibitors have been attributed to not only a decrease
in the local cardiac formation of angiotensin II, but
also a potentiation of kinin activity [4] and/or inhi-
bition of its degradation [5^11].
Bradykinin or its analogues are released from ki-
ninogens by the proteolytic action of kallikreins, ex-
ert their activities through binding to B1 or B2 re-
ceptors, and show a broad spectrum of biological
e¡ects including vasodilation, blood pressure reduc-
tion, smooth muscle relaxation and contraction, pain
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induction, and in£ammation [12,13]. Since concen-
trations of kinins in blood are very low, the forma-
tion of kinin by the kallikrein-kinin system has been
considered to operate mainly at the local tissue level
[14]. Consequently, a reliable method for the mea-
surement of kinin levels in tissue has demonstrated
levels much higher than in the circulation in rats,
suggesting the formation at local sites [15].
The role of kinins as possible mediators for the
endogenous cardioprotective mechanisms as well as
the therapeutic bene¢ts of ACE inhibitors in heart
failure is based on the existence of local kallikrein-
kinin system in cardiac tissues. Nolly et al. found
that slices of rat heart secreted a kininogen-like pro-
tein from which an immunoreactive kinin was re-
leased by trypsin digestion [16]. They also demon-
strated that tissue kallikrein mRNA was present in
both atrial and ventricular tissues of rat heart by
reverse transcription-polymerase chain reaction
(RT-PCR). Chao et al. reported that rat heart con-
tained a kininogen-like protein whose levels elevated
on the induction of acute in£ammation [17]. In addi-
tion, heart tissues and cardiomyocytes express func-
tional B2 receptors, suggesting that cardiomyocytes
are not only a source of kinins, but also a target for
kinin-mediated e¡ects [18^21].
The present study has been carried out to charac-
terize mRNA expressions of kininogens, kallikreins
and bradykinin receptors in rat heart in vivo and in
isolated cardiomyocytes in vitro. The results indicate
that rat cardiomyocytes as well as cardiac tissues
express mRNAs for these components and that var-
ious factors, such as lipopolysaccharide (LPS), cyclic
AMP and cytokines, in£uence their levels.
2. Materials and methods
2.1. Materials
The following chemicals were obtained from com-
mercial sources: LPS (Staphylococcus typhosa 0901)
from Difco (Detroit, MI); angiotensin II (AII) and
bradykinin from Peptide Institute (Osaka); dibutyryl
cyclic AMP (Bt2cAMP) from Boehringer-Mannheim-
Yamanouchi (Tokyo); phorbol 12-myristate 13-ace-
tate (PMA) from Nacalai tesque (Kyoto); recombi-
nant mouse interleukin-6 (IL-6; 1U108 U/mg) from
Genzyme. Recombinant human interleukin-1K (IL-1;
2U107 U/mg) and tumor necrosis factor K (TNF;
3U106 U/mg) were donated by Dainippon Pharma-
ceutical (Osaka).
2.2. Animals and LPS treatment
Sprague-Dawley male rats, weighing 140^160 g,
were injected intravenously with LPS at a dose of
0.5 mg/kg, then sacri¢ced at 12, 24, and 48 h. Ven-
tricles of the heart were isolated.
2.3. Culture of neonatal rat cardiomyocytes
Two- to 4-day-old Sprague-Dawley rats were used
for the isolation of cardiac myocytes and nonmyo-
cytes. The ventricular cardiac cells were dispersed in
Hanks’ balanced salt solution containing 0.04% col-
lagenase II and 0.06% pancreatin (Gibco) as previ-
ously reported [22]. Cardiac myocytes and nonmyo-
cytes were separately collected by the discontinuous
Percoll gradient method [22]. Brie£y, a discontinuous
gradient of Percoll consisting of 40.5% and 58.5%
was prepared in the Hanks’ balanced salt solution,
and cardiac cells were suspended in a layer of 58.5%
Percoll. After centrifugation at 850Ug for 30 min at
15‡C, myocytes migrated to the interface of discon-
tinuous layers, and nonmyocytes to the surface of the
layer of 40.5% Percoll. Puri¢ed cardiomyocytes or
nonmyocytes were plated at a density of 3U104
cells/cm2 in Dulbecco’s modi¢ed Eagle’s medium
(DME) containing 10% fetal bovine serum (FBS).
After culture for 24 h, the medium was replaced
with fresh DME containing 10% FBS with or with-
out various agents. After a further 24 h culture, cells
were harvested to extract total RNA. Using this
method, we routinely obtained contractile myocyte-
rich cultures with 90^95% myocytes as assessed using
immunocytochemistry with a monoclonal antibody
against L-myosin heavy chain.
2.4. Detection of kininogen and tissue kallikrein
mRNAs in myocardium and cardiomyocytes
Total RNA was extracted with acid guanidinium-
phenol-chloroform from isolated myocardium or cul-
tured cardiomyocytes [23]. We used RT-PCR fol-
lowed by Southern blotting for detecting mRNAs
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of kininogens and tissue kallikreins, such as high-
molecular-weight (H-), low-molecular-weight (L-)
and T-kininogens, true kallikrein (rKLK1), and
T-kininogenase (rKLK10), as described previously
[24].
2.5. Detection of bradykinin B1 and B2 receptor
mRNAs in myocardium and cardiomyocytes
Levels of B1 and B2 receptor mRNAs in myocar-
dium and cardiomyocytes were determined by RT-
PCR followed by Southern blotting as follows. Total
RNA (1 Wg) was reverse transcribed in a 20 Wl reac-
tion mixture containing 50 pmol of the reverse prim-
er, 2 Wl of 10 mM dNTP, 2 Wl of 10UPCR bu¡er (0.1
M Tris-HCl, pH 8.3, 500 mM KCl), 4 Wl of 25 mM
MgCl2, 1 unit of RNase inhibitor, and 1 unit of
cloned Moloney murine leukemia virus reverse tran-
scriptase (GeneAmp RNA PCR kit; Takara, Japan).
The RT reaction mixture was incubated at 42‡C for
15 min, 95‡C for 5 min, then 4‡C for 5 min to allow
synthesis of the ¢rst strand of cDNA. The cDNA
was ampli¢ed in a 100 Wl reaction mixture containing
50 pmol of the forward primer, 8 Wl of 10UPCR
bu¡er, 4 Wl of 25 mM MgCl2, and 2.5 units of Taq
DNA polymerase. Thirty-¢ve (B2 receptor) or 40 (B1
receptor) cycles proceeded as follows: denaturation
at 95‡C for 1 min, annealing at 60‡C for 1 min and
extension at 72‡C for 1 min. Then 8 Wl aliquots were
Southern blotted and autoradiographed using a Fuji
Film Bio Imaging Analyzer BAS1000 (Fuji Film,
Tokyo). The forward and reverse primers for B1 re-
ceptor were 5P-AGAAACCTCCCAAGACAGCA-3P
(nucleotides 26^45) and 5P-AGGAATGTGGGGA-
TGCTCAA-3P (nucleotides 679^698), respectively.
The forward and reverse primers for B2 receptor
were 5P-GGACCATGAAGGACTACAGG-3P (nu-
cleotides 891^910) and 5P-TAGGCCACGTAGGA-
ACTGAT-3P (nucleotides 1250^1269), respectively.
A speci¢c oligonucleotide for B1 receptor (5P-AGTA-
CAGGAGGTCAAAT-3P) was used as an internal
probe for hybridization. The probe for Southern hy-
bridization of B2 receptor was a 400 bp fragment of
B2 receptor cDNA.
3. Results
3.1. Detection of kininogen mRNAs in rat ventricular
myocardium
Three types of kininogens have been found so far
in mammalian species; these di¡er by molecular
weight and susceptibility to various kininogenases
[25]. Two of them, H- and L-kininogen, are present
throughout the mammalian lineage, whereas the
third type, T-kininogen, is considered to be unique
for the rat [25]. We attempted to detect H-, L-, and
T-kininogen mRNAs in rat myocardium by RT-PCR
and found a faint signal corresponding to T- and
L-kininogen cDNAs (Fig. 1), while no signal corre-
sponding to H-kininogen mRNA (data not shown).
Since we used a set of primers common for T- and
L-kininogen mRNAs, the RT-PCR products seemed
to be a mixture of cDNAs ampli¢ed from both T-
and L-kininogen mRNAs. Induction of systemic in-
£ammation following i.v. injection of LPS resulted in
increased levels of T/L-kininogen mRNA in rat ven-
tricle within 12 h (Fig. 1), while there was no induc-
tion of the H-kininogen mRNA during 48 h after the
LPS treatment (data not shown). To determine
Fig. 1. Southern blot analysis of cDNA products generated
from rat ventricular myocardium by RT-PCR using primers
and probe common for both T- and L-kininogen. Rats were in-
jected with LPS (0.5 mg/kg, i.v.), then four rats each were sacri-
¢ced at 12, 24 and 48 h by bleeding under ether anesthesia.
Four untreated animals were sacri¢ced as an untreated control.
Ventricular myocardium was isolated and total RNA was ex-
tracted. One Wg RNA samples were analyzed by RT-PCR (40
cycles) followed by Southern blotting using T-kininogen cDNA
as a probe, and two blots from two animals for each time point
after LPS injection are shown as representative of the results.
Bands in the upper panel represent a mixture of T- and L-kini-
nogen cDNAs. The bottom panel shows Southern blots of the
RT-PCR products ampli¢ed (25 cycles) for glyceraldehyde de-
hydrogenase (GAPDH) cDNA.
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whether RT-PCR products corresponding in size to
T- and L-kininogen cDNAs were actually composed
of these cDNAs, RT-PCR was carried out using a
£uorescent Cy5-labeled forward primer common for
both T- and L-kininogen cDNAs, then labeled
cDNA products were resolved by an ALFred DNA
sequencer (Pharmacia) on the basis of a 6 bp di¡er-
ence in cDNA products between T-(315 bp) and L-
(321 bp) kininogens as described previously [24]. The
RT-PCR products of untreated rat hearts revealed
two faint peaks corresponding to T- and L-kininogen
cDNAs (Fig. 2). cDNA products of LPS-treated rat
hearts comprised a clear large peak of T-kininogen
cDNA and a faint peak of L-kininogen cDNA (Fig.
2). Thus it was concluded that the rat myocardium
expressed both T- and L-kininogen mRNAs and that
LPS exclusively stimulated an expression of the
T-kininogen gene.
3.2. Detection of kininogen mRNAs in rat
cardiomyocytes in vitro
We recently reported that T-kininogen mRNA was
present in rat ¢broblasts [26] and vascular smooth
muscle cells [24], and found that the expression by
¢broblasts was stimulated by Bt2cAMP and cyto-
kines such as TNF, IL-1 and IL-6, while that by
vascular smooth muscle cells was enhanced by LPS,
PMA and angiotensin II. Thus it may be that these
cells rather than cardiomyocytes are the source of
kininogen mRNA in myocardium. To determine
which type of cell in rat myocardium expresses kini-
nogen mRNA, cardiac cells from neonatal rat heart
were separated into myocytes and nonmyocytes, then
cultured in vitro. As shown in the representative
autoradiogram in Fig. 3, although no signal corre-
sponding to T/L-kininogen mRNA was detected in
cultured myocytes, a distinct signal for T/L-kinino-
gen mRNA was observed in myocytes after 24 h
culture with LPS (0.5 Wg/ml) or Bt2cAMP (1 mM),
while not with PMA (10 WM) and cytokines, such as
TNF (500 U/ML), IL-1 (500 U/ml) and IL-6 (500 U/
ml). In contrast, a faint signal corresponding to T/L-
Fig. 2. Separation of RT-PCR products of T- and L-kininogen
mRNAs in rat ventricular myocardium by polyacrylamide gel
electrophoresis. Total RNA samples were prepared from myo-
cardium of untreated or LPS-pretreated rats (24 h, 0.5 mg/kg,
i.v.). The cDNAs transcribed from these samples were ampli¢ed
by 18 cycles using a £uorescence-labeled 5P-primer and non-la-
beled 3P-primer which were speci¢c for both T- and L-kinino-
gen cDNAs. The labeled products were separated by polyacryl-
amide gel electrophoresis and analyzed using an ALFred DNA
sequencer (Pharmacia; lower panel). The retention times for au-
thentic T-kininogen and L-kininogen cDNAs were 264 and 269
min, respectively (upper panel). Experiments were carried out
with RNA samples from four untreated and four LPS-treated
animals, and representative results are shown.
Fig. 3. Detection of kininogen mRNAs in rat cardiomyocytes
by RT-PCR followed by Southern blotting. Rat cardiomyocytes
were cultured with or without Bt2cAMP (1 mM), LPS (0.5 Wg/
ml), PMA (10 WM), TNF (500 U/ml), IL-1 (500 U/ml) or IL-6
(500 U/ml) for 24 h. Total RNA was extracted and subjected to
RT-PCR for T/L-kininogen mRNA (40 cycles) or H-kininogen
mRNA (40 cycles), then Southern blotting of the cDNA prod-
ucts was carried out using T-kininogen or H-kininogen cDNA
as a probe, respectively. Experiments were carried out 4 times
for each treatment, and representative results are shown.
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kininogen mRNA was also detected in nonmyocytes,
but the levels were not in£uenced by treatment with
LPS, Bt2cAMP, PMA and cytokines (data not
shown). Polyacrylamide gel electrophoresis of
cDNA products demonstrated that rat cardiomyo-
cytes expressed both T- and L-kininogen mRNAs,
and that levels of T-kininogen mRNA but not of
L-kininogen mRNA were increased by culture with
LPS or Bt2cAMP (data not shown). No detectable
signal for H-kininogen mRNA was found in either
cardiomyocytes or nonmyocytes (data not shown).
Western blotting using a rabbit anti-T-kininogen
antibody demonstrated that a T-kininogen-like pro-
tein with a molecular mass of 68 kDa was present in
the conditioned medium of cardiomyocytes that had
been cultured for 24 h with 1 mM Bt2cAMP, but not
in medium of untreated cardiomyocytes, suggesting
that rat cardiomyocytes secrete T-kininogen in re-
sponse to Bt2cAMP (data not shown). These results
indicate that rat cardiomyocytes are a source of T-
and L-kininogens, and that the expression of the T-
kininogen but not the L-kininogen gene is stimulated
by LPS and Bt2cAMP.
3.3. Detection of tissue kallikrein mRNAs in rat
ventricular myocardium and cardiomyocytes
Rats have more than ten members of the tissue
kallikrein family. Of these members, true kallikrein
encoded by rKLK1 has a kinin-liberating activity for
L- and H-kininogens [13], but not T-kininogen [27],
and T-kininogenase encoded by rKLK10 has a kini-
nogenase activity for T-kininogen [28]. Consistent
with a report by Nolly et al. [16], we con¢rmed the
presence of mRNA for true kallikreinin in rat myo-
cardium, and that the levels did not change after an
i.v. injection of LPS (Fig. 4). Since T-kininogen ap-
peared to be a major kininogen produced by rat
cardiac tissues, we tried to detect mRNA for
rKLK10. As shown in Fig. 4, T-kininogenase
mRNA was also detected in RNA samples from
rat myocardium, and the levels were not altered by
LPS injection. Tissue kallikrein mRNAs for rKLK1
and rKLK10 were detected in cultured cardiomyo-
cytes (Fig. 5), but not in nonmyocytes (data not
shown). Neither LPS (5 Wg/ml), PMA (10 nM) nor
cytokines (500 U/ml) in£uenced the levels of these
kallikrein mRNAs in cardiomyocytes, but Bt2cAMP
Fig. 4. Detection of tissue kallikrein mRNAs in rat ventricular
myocardium by RT-PCR followed by Southern blotting. RNA
samples were obtained from ventricular myocardium of un-
treated and LPS-pretreated rats, as described in the legend of
Fig. 1. One Wg of the sample was analyzed by RT-PCR fol-
lowed by Southern blotting for the true kallikrein (35 cycles),
T-kininogenase (40 cycles) and GAPDH (25 cycles). The ¢gure
shows two blots from two animals for each time point after
LPS injection as representative of the results.
Fig. 5. Detection of tissue kallikrein mRNAs in rat cardiomyo-
cytes by RT-PCR followed by Southern blotting. Rat cardio-
myocytes were cultured with or without Bt2cAMP (1 mM),
LPS (0.5 Wg/ml), PMA (10 WM), TNF (500 U/ml), IL-1 (500 U/
ml) or IL-6 (500 U/ml) for 24 h, then RNA samples were am-
pli¢ed by RT-PCR for true kallikrein (35 cycles), T-kininoge-
nase (40 cycles) and GAPDH (25 cycles) and Southern blotted.
Experiments were carried out 4 times for each treatment, and
representative results are shown.
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(1 mM) caused an increase in levels of T-kininoge-
nase mRNA (Fig. 5).
3.4. Detection of B1 and B2 receptor mRNAs in rat
ventricular myocardium and cardiomyocytes
By RT-PCR Southern hybridization, we detected
bradykinin B2 receptor mRNA in either rat myocar-
dium or cultured cardiomyocytes, and the levels were
not a¡ected by the injection of or culture with LPS
(Figs. 6 and 7). Although B1 receptor mRNA could
not be detected in untreated rat hearts, LPS injection
caused a marked induction of B1 receptor mRNA at
12^24 h (Fig. 6). B1 receptor mRNA was detectable
in cultured cardiomyocytes, and the level was in-
creased after culture with LPS (5 Wg/ml), IL-1 (500
U/ml) and TNF (500 U/ml), but decreased by IL-6
(500 U/ml) (Fig. 7). These agents did not a¡ect the
levels of B2 receptor mRNA in cardiomyocytes.
4. Discussion
The present study provides the ¢rst evidence that
rat cardiomyocytes are the source of T-kininogen, a
unique kininogen in the rat, but poor sources of H-
and L-kininogens. T-kininogen has been character-
ized as a protein highly homologous in structure to
rat L-kininogen as well as one of the acute-phase
proteins in the rat [27,29]. This protein is produced
not only by hepatocytes but also by ¢broblasts and
vascular smooth muscle cells [24,26]. In fact, T-kini-
nogen mRNA has been detected in several tissues of
rats, such as the liver, lung, kidney and heart [17,30].
However, Barka and van der Noen have reported
that the T-kininogen gene is not expressed in rat
heart on the basis of ¢ndings that T-kininogen
mRNA was not detectable by a sensitive RT-PCR
method in cardiac tissue of either normal or turpen-
tine-injected rats [31]. In contrast to their results, we
detected T-kininogen mRNA in rat ventricular my-
ocardium and found that the level was increased
after injection of LPS. Furthermore, cardiomyocytes
from neonatal rat hearts not only contained T-kini-
nogen mRNA but also secreted immunoreactive T-
Fig. 7. Detection of bradykinin B1 and B2 receptor mRNAs in
rat cardiomyocytes by RT-PCR followed by Southern blotting.
Rat cardiomyocytes were cultured with or without Bt2cAMP (1
mM), LPS (0.5 Wg/ml), PMA (10 WM), TNF (500 U/ml), IL-1
(500 U/ml) or IL-6 (500 U/ml) for 24 h, then RNA samples
were ampli¢ed by RT-PCR for B1 receptor (40 cycles), B2 re-
ceptor (35 cycles) and GAPDH (25 cycles) followed by South-
ern blotting. Experiments were carried out 4 times for each
treatment, and representative results are shown.
Fig. 6. Detection of bradykinin B1 and B2 receptor mRNAs in
rat ventricular myocardium by RT-PCR followed by Southern
blotting. RNA samples were obtained from the ventricular my-
ocardium of untreated and LPS-pretreated rats, as described in
the legend of Fig. 1. One Wg of the sample was analyzed by
RT-PCR followed by Southern blotting for B1 receptor (40
cycles), B2 receptor (35 cycles) and GAPDH (25 cycles). The
¢gure shows two blots from two animals for each time point
after LPS injection as representative of the results.
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kininogen in culture. Since we used the same primers
for detecting T-kininogen mRNA as they used, the
reason for this discrepancy is not obvious. Interest-
ingly, an addition of LPS to cultures resulted in in-
creased levels of T-kininogen mRNA in cardiomyo-
cytes, suggesting that LPS acts directly on
cardiomyocytes to induce the T-kininogen gene
rather than indirectly by LPS-induced mediators,
such as IL-1 and IL-6. This may be why the T-kini-
nogen mRNA level was not elevated in rat heart
even after induction of in£ammation by turpentine
[31]. The fact that little T-kininogen mRNA was de-
tected in nonmyocytes in the presence or absence of
LPS in vitro suggests that cardiomyocytes are the
major cells expressing the T-kininogen gene in rat
heart.
When RT-PCR products ampli¢ed by primers
common for T- and L-kininogen mRNAs were re-
solved on polyacrylamide gel electrophoresis, we ob-
served a faint peak with a retention time correspond-
ing to L-kininogen cDNA in RNA samples,
suggesting the presence of L-kininogen mRNA in
cardiomyocytes. However, the levels were very low
in comparison to the T-kininogen mRNA level and
did not change after LPS treatment in vivo or in
vitro, making the physiological relevance unclear.
In addition, we could not detect H-kininogen
mRNA in either ventricular myocardium or cardio-
myocytes, even by a sensitive RT-PCR method. Thus
it is likely that rat cardiomyocytes are poor sources
of L- and/or H-kininogens. Nolly et al. reported that
rat cardiac slices secreted a kininogen which liberated
bradykinin-like immunoreactivity by trypsin diges-
tion [16], providing the ¢rst evidence for the presence
of cardiac kininogen. It is well known that T-kinino-
gen releases Ile-Ser-bradykinin by trypsin digestion
and that this bradykinin analogue is recognized by
polyclonal anti-bradykinin antibodies. Thus, our
¢ndings, together with the evidence described above,
indicate that the cardiac kininogen in the rat is
mainly T-kininogen, not H- and L-kininogens.
As demonstrated by Nolly et al., rat cardiac tissues
and cardiomyocytes synthesize and secrete a tissue
kallikrein corresponding to the true kallikrein [16].
In addition to this subtype of tissue kallikreins, we
found the mRNA of T-kininogenase to be present in
rat cardiomyocytes. Ma et al. have demonstrated
that T-kininogenase is expressed in the rat at high
levels in the submandibular gland and low levels in
the kidney, but not at all in seven other tissues, in-
cluding the heart [28]. In contrast, our present study
showed that mRNA for T-kininogenase was detect-
able in rat cardiomyocytes as well as ventricular my-
ocardium. Since we used the same primers for detect-
ing T-kininogenase as reported by Ma et al., the
discrepancy in the ¢ndings is probably due to the
di¡erences in conditions for RT-PCR, including tem-
perature, reaction times and PCR cycles. Of interest,
the levels of T-kininogenase mRNA in cardiomyo-
cytes elevated after the culture with Bt2cAMP.
Thus the treatment of cardiomyocytes with
Bt2cAMP induced the gene expression of not only
T-kininogen but also T-kininogenase, suggesting
that the elevation of intracellular cAMP levels in
cardiomyocytes results in the increased production
of both T-kininogen and T-kininogenase. In fact,
we observed increased levels of T-kininogen mRNA
in cardiomyocytes after culture with 1038 M isopro-
terenol (data not shown). Since T-kininogenase lib-
erates Ile-Ser-bradykinin from T-kininogen, one may
speculate that the cardiac kallikrein-kinin system in
the rat comprises T-kininogen and T-kininogenase
rather than H/L-kininogen and true tissue kallikrein.
There are at least two subtypes of bradykinin re-
ceptors, B1 and B2, in mammalian tissues; the ma-
jority of the classical actions of bradykinin have been
attributed to an activation of B2 receptor, whereas
B1 receptors, unique as an inducible receptor acti-
vated by in£ammatory stimuli, appear to be involved
in chronic in£ammatory responses [32^34]. The exis-
tence of these two subtypes of bradykinin receptors
in cardiac tissues has been con¢rmed by means of
radioligand binding [18]. Consistent with ¢ndings
by other investigators [35^37], we detected B2 recep-
tor mRNA in ventricular myocardium of either un-
treated or LPS-injected rats, while detecting B1 re-
ceptor mRNA only after injection of LPS. Similar
results were obtained in the in vitro experiments us-
ing rat cardiomyocytes in which mRNA levels for B1
receptor but not for B2 receptor were elevated after
cultures with LPS. Ni et al. reported that the 5P-
£anking region of the human B1 receptor showed
promoter activity inducible by LPS and proin£am-
matory cytokines, such as IL-1 or TNF, in vascular
smooth muscle cells [38]. As shown in the present
study, the exposure of rat cardiomyocytes to LPS,
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IL-1 and TNF in vitro also produced an elevation in
the B1 receptor mRNA level, suggesting that the in-
ducible process for B1 receptor seen in vascular
smooth muscle cells exists in cardiomyocytes. It
should be noted that B1 receptor mRNA was detect-
able in untreated cells, suggesting the induction of B1
receptor following the isolation and in vitro incuba-
tion of cardiomyocytes [39^42]. In contrast to IL-1
and TNF, another proin£ammatory cytokine, IL-6,
suppressed B1 receptor mRNA levels in cultured car-
diomyocytes, suggesting a potential regulatory role
for IL-6 in the upregulation of B1 receptors follow-
ing tissue injury or in£ammation. Further studies will
be needed to clarify the importance of IL-6 to the
pathophysiological role of the B1 receptor.
In conclusion, the present study has demonstrated
that cardiomyocytes in rat ventricular myocardium
express mRNAs for the kallikrein-kinin system,
such as kininogens, kallikreins and B1/B2 receptors.
However, this system in myocardium seems to be
unique to the rat in that the only kininogen synthe-
sized locally in myocardium appears to be T-kinino-
gen, a unique kininogen in the rat. Ile-Ser-bradykinin
may possibly be generated in rat heart and serve as
the cardioprotective kinin. Since this kinin-generat-
ing system is not present in humans and other ani-
mals, further studies are needed to clarify the exis-
tence of the independent kallikrein-kinin system in
cardiomyocytes of these species.
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